Global Custom Market Research Reports Provider Company

phone

Ignyta Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 27 Aug 2018
  • Number of Pages: 68
  • Category: Company Profile
  • Country: United States of America
Summary

Ignyta Inc (Ignyta), formerly NexDx Inc is a cancer care service provider. The company discovers, develops and commercializes new drugs targeting activated genes in cancer cells. It develops products using integrated therapeutic (Rx) and companion diagnostic (Dx) technology. Ignytas pipeline products include entrectinib, RXDX-105, taladegib and RXDX-106. The companys entrectinib product designed to target cancers harboring activating molecular alterations. Its RXDX-106 is a novel small molecule immunomodulatory agent with potent anti-tumor activity. Ignyta offers clinical trials and research and development services. The company also develops trailblaze diagnostic programs. It serves cancer patients and pharmaceuticals industries. Ignytais headquartered in San Diego, California, the US.

Ignyta Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ignyta Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Ignyta Acquires Four Oncology R&D Assets from Cephalon 12
Venture Financing 14
NexDx Raises US$5.5 Million In Series B Financing 14
Partnerships 15
Ignyta and Institut Curie Enter into Partnership 15
Ignyta Enters into Research Agreement with Moffitt Cancer Center 16
Merger 17
Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 17
Licensing Agreements 18
Ignyta Amends Licensing Agreement with Eli Lilly 18
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 20
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 22
Equity Offering 23
Ignyta Prices Public Offering of Shares for USD160 Million 23
Ignyta Raises USD88.4 Million in Public Offering of Shares 25
Ignyta Raises USD57.5 Million in Public Offering of Shares 27
Ignyta Raises USD30 Million in Private Placement of Shares 29
Ignyta Raises USD75 Million in Public Offering of Shares 30
Ignyta Raises USD42 Million in Private Placement of Shares 32
Ignyta Completes Public Offering Of Shares For US$55.2 Million 33
Ignyta Completes Private Placement Of Shares For US$7.8 Million 34
Ignyta Completes Private Placement Of Shares For US$46.2 Million 35
Acquisition 36
Roche to Acquire Ignyta for USD1.7 Billion 36
Ignyta Acquires Actagene Oncology 38
Ignyta Inc - Key Competitors 39
Ignyta Inc - Key Employees 40
Ignyta Inc - Locations And Subsidiaries 41
Head Office 41
Recent Developments 42
Financial Announcements 42
Nov 07, 2017: Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results 42
Aug 08, 2017: Ignyta Announces Second Quarter 2017 Company Highlights and Financial Results 44
May 01, 2017: Ignyta Announces First Quarter 2017 Company Highlights and Financial Results 46
Mar 14, 2017: Ignyta Announces Full Year 2016 Company Highlights and Financial Results 48
Product News 50
05/15/2017: Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration 50
Product Approvals 51
Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors 51
Jul 10, 2017: Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors 52
Clinical Trials 53
Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer 53
Oct 17, 2017: Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer 54
Sep 27, 2017: Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer 55
Sep 11, 2017: Ignyta to Provide Update on Entrectinib at ESMO 2017 Congress 56
Sep 07, 2017: Ignyta To Host Conference Call And Live Webcast On September 11 To Provide Pipeline Review, Including Lead Candidate Entrectinib 57
Sep 06, 2017: Ignyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program 58
Aug 30, 2017: Ignyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017 59
Apr 27, 2017: Ignyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions 60
Apr 24, 2017: Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27, 2017 61
Apr 04, 2017: Ignyta Announces New Data on Entrectinib at the 2017 AACR Annual Meeting 62
Mar 30, 2017: Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology 63
Mar 28, 2017: Ignyta Announces Presentation of Entrectinib at the 2017 AACR Annual Meeting 64
Mar 03, 2017: Angsanas RNA-based fusions cancer panel selected for Ignytas STARTRK2 clinical trial in Asia-Pacific 65
Feb 09, 2017: Ignytas Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery 66
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List Of Tables


Ignyta Inc, Pharmaceuticals & Healthcare, Key Facts 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ignyta Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ignyta Acquires Four Oncology R&D Assets from Cephalon 12
NexDx Raises US$5.5 Million In Series B Financing 14
Ignyta and Institut Curie Enter into Partnership 15
Ignyta Enters into Research Agreement with Moffitt Cancer Center 16
Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 17
Ignyta Amends Licensing Agreement with Eli Lilly 18
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 20
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 22
Ignyta Prices Public Offering of Shares for USD160 Million 23
Ignyta Raises USD88.4 Million in Public Offering of Shares 25
Ignyta Raises USD57.5 Million in Public Offering of Shares 27
Ignyta Raises USD30 Million in Private Placement of Shares 29
Ignyta Raises USD75 Million in Public Offering of Shares 30
Ignyta Raises USD42 Million in Private Placement of Shares 32
Ignyta Completes Public Offering Of Shares For US$55.2 Million 33
Ignyta Completes Private Placement Of Shares For US$7.8 Million 34
Ignyta Completes Private Placement Of Shares For US$46.2 Million 35
Roche to Acquire Ignyta for USD1.7 Billion 36
Ignyta Acquires Actagene Oncology 38
Ignyta Inc, Key Competitors 39
Ignyta Inc, Key Employees 40

List Of Figures


Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ignyta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ignyta Inc, Medical Devices Deals, 2012 to YTD 2018 10

ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and foetal health products. The company develops products for use in rare cell diagnostics that enable early, accurate

View Report

US Physical Therapy Inc (USPh) operates outpatient physical and occupational therapy clinics that offer pre-and post-operative care. The company provides treatment for orthopedic-related disorders, preventative care, sports-related injuries, rehabilitation of

View Report

University of Copenhagen (UCPH) is a university and research institution that offers educational and research programs and services. The university services include graduate and undergraduate courses, research programs, masters programs,

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports